UConn Innovation Portal– A homegrown UConn startup has made major advancements thanks to university entrepreneurship programs, including recently being accepted into UConn’s competitive Technology Incubation Program.
Stamford Advocate– New York City this week added a new dimension to the legal crisis facing Purdue Pharma.
The nation’s largest city is suing several pharmaceutical firms including Stamford’s Purdue, one of the most prominent of the many lawsuits that blame the company for fueling the opioid crisis.
UConn Innovation Portal– UConn alumnus Tim Myles ’14 Ph.D. (ENG) has taken advantage of several NSF I-Corps programs to help commercialize a non-invasive, clinically accurate device that detects and monitors the status of chronic illnesses through analysis of exhaled breath. Hear about his experience with I-Corps, innovation, and entrepreneurship.
Stamford Advocate– The country’s second-largest cable company wants to be more than a distributor.
Charter Communications’ announcement earlier this month that it had created and filled a new senior vice president position to oversee original content points to its increasing focus on producing its own programming. Industry experts are not surprised that Charter is focusing more on production in a shifting media landscape, but some question the effectiveness of the strategy.
PR Newswire– For families faced with the difficult decision of placing a loved one in a nursing home, a government rating system is often the only source of information to determine which facilities are the best. However, a new study of nursing homes in California, the nation’s largest system, by faculty at Florida Atlantic University and the University of Connecticut, found that some nursing homes inflate their self-assessment reporting to improve their score in the Five-Star Quality Rating System employed by Medicare to help consumers.
Business School Professor Predicts UConn is on Cusp of Powerful Entrepreneurial Growth
David Noble, a professor-in-residence in the management department at the School of Business, has been named the director of the new Peter J. Werth Institute for Entrepreneurship and Innovation at UConn. Continue Reading
Our final day in Tel Aviv was bittersweet, as we knew our incredible journey was coming to an end. We started the day meeting at YL Ventures, a venture capital (VC) firm like many in Israel that focused on early-stage investing. I was astounded that while the US was trending towards less early/seed-stage capital and much more later-stage investments, Israel seemed to embrace their unique VC ecosystem.
UConn Today– Immunotherapies are promising in theory, but often not in practice. In fact according to experts, they actually only work 10 percent of the time in the treatment of cancer – at best. Yet, while immunotherapy drugs may only help a minority of patients, those who do respond often do extremely well. As a result, many scientists are working to tap into the treatment’s benefits for a wider group of patients.